sj-docx-1-cat-10.1177_10760296231184216 - Supplemental material for Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya

Supplemental material, sj-docx-1-cat-10.1177_10760296231184216 for Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya by Dennis Njuguna, BPharm, Francis Nwaneri, MD, Allyson C. Prichard, PharmD, Imran Manji, BPharm, MPH, Gabriel Kigen, BPharm, MPhil, PhD, Naftali Busakhala, MBChB, MMed, Samuel Nyanje,BSc, Emily O'Neil, PharmD and Sonak D. Pastakia, PharmD, MPH, PhD in Clinical and Applied Thrombosis/Hemostasis</p

Additional file 1: of Using pay for performance incentives (P4P) to improve management of suspected malaria fevers in rural Kenya: a cluster randomized controlled trial

Table of intracluster correlation coefficients (ICCs) for main study endpoints at month 12. (PDF 27 kb

Additional file 2: of Using pay for performance incentives (P4P) to improve management of suspected malaria fevers in rural Kenya: a cluster randomized controlled trial

A brief summary of estimating risk difference in our study for comparing to risk differences calculated for other behavior change interventions. (DOCX 143 kb

Flow diagram of enrollment and12-months follow-up.

<p>Legend. AF = atrial fibrillation, LTFU = lost to follow up.</p

Comparison of outcomes of atrial fibrillation patients.

<p>Comparison of outcomes of atrial fibrillation patients.</p

Medication use before study entry for atrial fibrillation patients.

<p>Medication use before study entry for atrial fibrillation patients.</p

Baseline characteristics of atrial fibrillation patients.

<p>Baseline characteristics of atrial fibrillation patients.</p